Skip to main content

Table 2 Included studies and response to therapy

From: The pathogenesis of renal injury and treatment in light chain deposition disease

Therapy

Study

Total

With MM

LC type

Age

Creatinine clearance (mL/min)

Median creatinine mg/dL

24 h urinary protein excretion

CR (%)

LC deposits

Surviving patients (%)

Median follow up (months)

κ

λ

Pre

Posta

Pre

Posta

MEVP

Komatsuda [44]

1

1

1

0

64

44

73

2.0

1.0

Decease to less than 0.1

100

0

100

70

BD

Kastritis [47]

4

0

3

1

57.85 (range 46–67)

–

–

2.9

1.9

Reduction 89.5%

50

2/4

100

11.3 (range 2–16)

HDM + ASCT

Kastritis [47]

3

0

3

0

51.3 (range 46–56)

–

–

–

–

Only trace proteinuria

100

–

100

14.3 (range 12–16)

After BD

González –López [23]

1

0

1

0

63

17

50

5.2

2.31

–

100

0

100

54

Tovar [24]

3

0

1

2

49 (range 46–56)

–

–

2.14

1.27

Reduction 84%

67

0

100

28.7 (range 12–40)

ASCT after CBD

Smita [48]

1

0

1

0

33

–

–

4.9

1.60

–

100

0

100

12

and VLD

Weichman [40]

5

0

3

2

44.5 (range 36–51)

–

–

55

2 patients

HD/PD

Reduction 75.3%

80

0

100

12 (range 4–29)

HDM + ASCT

Lorenz [46]

6

3

5

1

43.5 (33–61)

–

–

2.4

1 patient HD

Reduction 92%

100

–

83.3

31.7

Pozzi [4]

5

4

–

–

58 ± 14.2

–

–

–

1 patient uremia

–

–

–

100

27.5

  1. Complete hematologic response (CR) is defined as the complete disappearance of monoclonal Ig protein in serum and urine, the normalization of light chain ratio without serum, and the < 5% plasma cells without clonal advantage of k or l subtype demonstrated by bone marrow biopsy
  2. MM Multiple myeloma, LC light chain, MEVP melphalan + cyclophos + phamide + vincristine + prednisolone, BD bortezomib + dexamethasone, HDM high-does melphalan, ASCT autologous stem cell transplantation, CBD cyclophosphamide + bortezomib + dexamethasone, VLD bortezomib + lenalidomide + dexamethasone
  3. aPost-treatment values are from the last follow-up visits